DK3518948T3 - Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira - Google Patents
Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira Download PDFInfo
- Publication number
- DK3518948T3 DK3518948T3 DK17857734.2T DK17857734T DK3518948T3 DK 3518948 T3 DK3518948 T3 DK 3518948T3 DK 17857734 T DK17857734 T DK 17857734T DK 3518948 T3 DK3518948 T3 DK 3518948T3
- Authority
- DK
- Denmark
- Prior art keywords
- oncolytic
- enhancing
- spread
- growth
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662403586P | 2016-10-03 | 2016-10-03 | |
PCT/CA2017/051176 WO2018064762A1 (en) | 2016-10-03 | 2017-10-03 | Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3518948T3 true DK3518948T3 (da) | 2023-07-24 |
DK3518948T5 DK3518948T5 (da) | 2024-09-02 |
Family
ID=61830768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17857734.2T DK3518948T5 (da) | 2016-10-03 | 2017-10-03 | Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira |
Country Status (11)
Country | Link |
---|---|
US (1) | US11517598B2 (da) |
EP (1) | EP3518948B1 (da) |
CN (1) | CN110022889B (da) |
CA (1) | CA3034983A1 (da) |
DK (1) | DK3518948T5 (da) |
ES (1) | ES2950435T3 (da) |
FI (1) | FI3518948T3 (da) |
HR (1) | HRP20230698T1 (da) |
PT (1) | PT3518948T (da) |
SI (1) | SI3518948T1 (da) |
WO (1) | WO2018064762A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3116192A1 (en) * | 2018-11-06 | 2020-05-14 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
MX2021005667A (es) * | 2018-11-14 | 2021-10-13 | Broad Inst Inc | Composiciones de vanadio y métodos para el tratamiento del cáncer. |
CN113876957A (zh) * | 2020-07-01 | 2022-01-04 | 青岛海洋生物医药研究院股份有限公司 | Stat2磷酸化水平调节剂的用途 |
US20240293352A1 (en) * | 2021-05-07 | 2024-09-05 | Ottawa Hospital Research Institute | Pharmaceutical compositions comprising vanadium salts |
CN114427010A (zh) * | 2021-12-28 | 2022-05-03 | 云舟生物科技(广州)股份有限公司 | 一种检测水疱性口炎病毒滴度的引物、试剂盒及方法 |
WO2023225268A1 (en) * | 2022-05-19 | 2023-11-23 | The University Of Chicago | Vanadyl sulfate compositions and methods of use therefor for the treatment and prevention of aging-related diseases and cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9814036D0 (en) * | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
JP2003530301A (ja) | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
ES2233600T5 (es) | 2000-01-21 | 2009-06-22 | Biovex Limited | Cepas de virus del herpes. |
AU2001279264B2 (en) | 2000-06-26 | 2005-04-28 | University Of Ottawa | Purging of cells using viruses |
ATE472733T1 (de) | 2000-11-09 | 2010-07-15 | Oncolytics Biotech Inc | Verfahren zur beurteilung von zellulären proliferativen erkrankungen |
MXPA03010278A (es) | 2001-05-11 | 2004-12-06 | Wellstat Biologics Corp | Terapia con virus oncolitico. |
US20040115170A1 (en) | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
CN101161248B (zh) * | 2007-11-06 | 2011-05-04 | 辽宁大学 | 一种抗乙型肝炎病毒药物的制备方法 |
CU20080028A6 (es) * | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
JP6121910B2 (ja) * | 2011-01-04 | 2017-04-26 | シラジェン バイオセラピューティクス インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成 |
CN111373032A (zh) * | 2017-11-24 | 2020-07-03 | 渥太华医院研究所 | 用于增强干扰素敏感性病毒的生产、生长、扩散或溶瘤和免疫治疗功效的组合物和方法 |
-
2017
- 2017-10-03 WO PCT/CA2017/051176 patent/WO2018064762A1/en unknown
- 2017-10-03 HR HRP20230698TT patent/HRP20230698T1/hr unknown
- 2017-10-03 US US16/339,294 patent/US11517598B2/en active Active
- 2017-10-03 EP EP17857734.2A patent/EP3518948B1/en active Active
- 2017-10-03 ES ES17857734T patent/ES2950435T3/es active Active
- 2017-10-03 SI SI201731381T patent/SI3518948T1/sl unknown
- 2017-10-03 PT PT178577342T patent/PT3518948T/pt unknown
- 2017-10-03 CN CN201780073469.XA patent/CN110022889B/zh active Active
- 2017-10-03 DK DK17857734.2T patent/DK3518948T5/da active
- 2017-10-03 FI FIEP17857734.2T patent/FI3518948T3/fi active
- 2017-10-03 CA CA3034983A patent/CA3034983A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018064762A1 (en) | 2018-04-12 |
US11517598B2 (en) | 2022-12-06 |
ES2950435T3 (es) | 2023-10-10 |
CN110022889B (zh) | 2024-05-10 |
DK3518948T5 (da) | 2024-09-02 |
SI3518948T1 (sl) | 2023-09-29 |
CN110022889A (zh) | 2019-07-16 |
EP3518948A1 (en) | 2019-08-07 |
PT3518948T (pt) | 2023-07-17 |
US20190231832A1 (en) | 2019-08-01 |
EP3518948A4 (en) | 2020-06-24 |
FI3518948T3 (fi) | 2023-07-18 |
CA3034983A1 (en) | 2018-04-12 |
HRP20230698T1 (hr) | 2023-10-13 |
EP3518948B1 (en) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3510157T5 (da) | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse | |
DK3782639T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
IL272089B1 (en) | Compounds, compositions and methods | |
DK3356390T3 (da) | Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer | |
DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
DK3842442T3 (da) | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet | |
DK3518948T3 (da) | Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira | |
DK4104687T5 (da) | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe | |
DK3012322T3 (da) | Gendeleteret stamme af porcint pseudorabiesvirus, vaccinesammensætning og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
DK3506886T3 (da) | Højkoncentrerede lavviskositets-masp-2-inhiberende antistofformuleringer, kits og fremgangsmåder | |
DK4011887T3 (da) | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3307872T3 (da) | Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober | |
DK3390430T3 (da) | Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3262008T3 (da) | Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed | |
DK3207130T3 (da) | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3172233T3 (da) | Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer | |
DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
DK3394272T5 (da) | Sammensætninger og fremgangsmåder til effektiv målretning af transgener | |
DK3606929T3 (da) | Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme | |
ES3014482T3 (en) | Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses |